Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Incyte’s ruxolitinib (Jakafi, approved November 2011) and Bristol Myers Squibb’s (BMS’s) fedratinib (Inrebic, approved August 2019) are the only FDA-approved drugs to treat MF. Although Jakafi is an important therapeutic option, discontinuation and/or loss of response may occur, and it does not address all MF symptoms. Therefore, significant market opportunity remains for additional safe and tolerable treatments that can manage the full spectrum of MF symptoms, as well as for treatments for patients with baseline thrombocytopenia and anemia. This report explores the current prescribing practices for MF, the various factors driving treatment decisions, and the changes in prescribing that are expected to occur in the coming year.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
GEOGRAPHY: United States
PRIMARY RESEARCH: Survey of 101 U.S. hematologists
KEY DRUGS COVERED: Ruxolitinib (Incyte’s Jakafi); fedratinib (BMS’s Inrebic); hydroxyurea; interferons
KEY INSIGHTS PROVIDED: